Erasca, Inc.
Case Overview
50 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 08/10/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Erasca, Inc. |
| Court: | Court: Southern District of California |
| Case Number: | Case Number: 3:26cv03481 |
| Class Period: | Class Period: 01/14/2025 - 04/26/2026 |
| Ticker: | Ticker: ERAS |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) securities during the period of January 14, 2925 through April 26, 2026, inclusive (“the Class Period”).
The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015. The company presented ERAS-0015 as a potential “best-in-class” therapy and highlighted purportedly superior preclinical results compared to Revolution Medicines’ competing drug candidate, RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposing the Company to patent and trade secret disputes, and lacked a reasonable basis.
On April 27, 2026, Erasca disclosed in a Form 8-K that it had received a letter from legal counsel for RevMed alleging that Erasca’s ERAS0015 infringes a RevMed patent (U.S. Patent No. 12,409,225) and is connected to alleged trade secret misappropriation. RevMed also alleged that Erasca had “improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures” and demanded Erasca cease making “deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236.” Erasca stated that it believes the assertions are without merit and intends to contest the allegations. On this news, the price of Erasca shares declined by $2.34 per share, or approximately 11%, from $21.49 per share on April 24, 2026 to close at $19.15 on April 27, 2026.
On April 27, 2026, Erasca filed a separate Form 8-K reporting preliminary Phase 1 clinical data for ERAS-0015 and disclosing that one patient that received 24 mg of ERAS-0015 had died approximately a month after starting ERAS-0015. The patient was classified as a “Grade 3 TRAE of pneumonitis” that “progressed to Grade 5 after withdrawal of supportive care per patient decision.” Erasca further stated that comparisons between ERAS-0015 and other product candidates, including RMC-6236, were based on cross-study analyses and “not based on any head-to-head clinical trials,” and that such comparisons are “inherently limited and such data may not be directly comparable.” On this news, the price of Erasca shares declined by $9.25 per share, or approximately 48%, from $19.15 per share on April 27, 2026 to close at $9.90 on April 28, 2026.
The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015. The company presented ERAS-0015 as a potential “best-in-class” therapy and highlighted purportedly superior preclinical results compared to Revolution Medicines’ competing drug candidate, RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposing the Company to patent and trade secret disputes, and lacked a reasonable basis.
On April 27, 2026, Erasca disclosed in a Form 8-K that it had received a letter from legal counsel for RevMed alleging that Erasca’s ERAS0015 infringes a RevMed patent (U.S. Patent No. 12,409,225) and is connected to alleged trade secret misappropriation. RevMed also alleged that Erasca had “improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures” and demanded Erasca cease making “deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236.” Erasca stated that it believes the assertions are without merit and intends to contest the allegations. On this news, the price of Erasca shares declined by $2.34 per share, or approximately 11%, from $21.49 per share on April 24, 2026 to close at $19.15 on April 27, 2026.
On April 27, 2026, Erasca filed a separate Form 8-K reporting preliminary Phase 1 clinical data for ERAS-0015 and disclosing that one patient that received 24 mg of ERAS-0015 had died approximately a month after starting ERAS-0015. The patient was classified as a “Grade 3 TRAE of pneumonitis” that “progressed to Grade 5 after withdrawal of supportive care per patient decision.” Erasca further stated that comparisons between ERAS-0015 and other product candidates, including RMC-6236, were based on cross-study analyses and “not based on any head-to-head clinical trials,” and that such comparisons are “inherently limited and such data may not be directly comparable.” On this news, the price of Erasca shares declined by $9.25 per share, or approximately 48%, from $19.15 per share on April 27, 2026 to close at $9.90 on April 28, 2026.